TCD-717, the Company's leading product, is a first-in-class, precisely-targeted small molecule that is administered intravenously (IV) and effectively inhibits ChoKα.
The drug embodies the Company's approach of combining Personalized Medicine and Targeted Therapy. The patient population eligible for treatment will be identified by testing tumors for ChoKα overexpression whilst treatment with TCD-717 will specifically destroy the cancer cells and merely arrests temporarily the life cycle of normal cells.
Studies so far have demonstrated that TCD-717 has significant effects on the in-vivo inhibition of tumor growth in four major cancer types (lung, breast, colon and bladder). In-vitro studies have additionally shown the efficacy of TCD-717 as a treatment for cervix, epidermal, pancreas, liver, ovary, bone, brain and kidney tumors indicating it has an even broader spectrum treatment potential.
TCD-717 is currently undergoing evaluation in a Phase I clinical trial designed to primarily assess the safety and tolerability, pharmacokinetics and preliminary efficacy of TCD-717 given by intravenous infusion in patients with advanced solid tumors. The study has been approved by the FDA as part of an Investigational New Drug (IND) application, and is being conducted in two medical centers in the U.S.
All rights reserved. 2011 TCD Pharma                                         Legal Statement                                                          Designed by Freeman y la luz